The first C1-INH therapy indicated to help prevent HAE attacks in children (6 years of age and older), teenagers and adults

With hereditary angioedema (HAE), it takes courage to embrace a preventive approach. CINRYZE® (C1 esterase inhibitor [human]) was the first FDA-approved preventive treatment that can start at age 6, helping to reduce HAE attacks earlier in life.

Start with HAE attack prevention.

Learn how CINRYZE can reduce the frequency and severity of HAE attacks in children as young as six.

Learn More


Learn about proven prevention with CINRYZE and explore resources to support your journey with HAE.

Learn about use with children

Find out more about the expanded use of CINRYZE to include children aged 6 to 11.

Learn More

Learn about self-administration

Before you or your caregiver administers CINRYZE, you will need to be trained by a healthcare professional.

Find Out More

Get product support

OnePath® provides eligible patients prescribed a Takeda HAE therapy with dedicated Patient Support Managers to assist with your product support needs.

Learn about OnePath

See our resources

Explore helpful materials to educate you and your caregiver on HAE and CINRYZE.

Start Browsing